Eagle Global Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$332K Hold
13,800
0.01% 232
2026
Q1
$388K Hold
13,800
0.01% 224
2025
Q4
$344K Buy
13,800
+250
+2% +$6.3K 0.01% 238
2025
Q3
$345K Hold
13,550
0.01% 237
2025
Q2
$328K Hold
13,550
0.01% 227
2025
Q1
$343K Hold
13,550
0.01% 224
2024
Q4
$359K Buy
+13,550
New +$368K 0.01% 217
2024
Q3
Sell
-7,721
Closed -$216K 247
2024
Q2
$216K Sell
7,721
-1,002
-11% -$27.6K 0.01% 227
2024
Q1
$242K Sell
8,723
-1,025
-11% -$28.4K 0.01% 217
2023
Q4
$281K Sell
9,748
-1,905
-16% -$57.6K 0.02% 201
2023
Q3
$387K Sell
11,653
-250
-2% -$8.84K 0.03% 181
2023
Q2
$437K Sell
11,903
-25
-0.2% -$973 0.03% 173
2023
Q1
$487K Sell
11,928
-99
-0.8% -$4.28K 0.03% 162
2022
Q4
$616K Sell
12,027
-491
-4% -$23.5K 0.04% 153
2022
Q3
$548K Sell
12,518
-117,206
-90% -$5.7M 0.04% 154
2022
Q2
$6.8M Sell
129,724
-10,868
-8% -$554K 0.5% 58
2022
Q1
$7.28M Sell
140,592
-467
-0.3% -$24.2K 0.45% 62
2021
Q4
$8.33M Buy
141,059
+130,215
+1,201% +$6.45M 0.52% 59
2021
Q3
$466K Sell
10,844
-150
-1% -$6.64K 0.03% 175
2021
Q2
$431K Sell
10,994
-300
-3% -$11.7K 0.03% 189
2021
Q1
$409K Sell
11,294
-541
-5% -$19.2K 0.03% 196
2020
Q4
$436K Sell
11,835
-639
-5% -$23.4K 0.03% 167
2020
Q3
$434K Sell
12,474
-291
-2% -$10.2K 0.04% 153
2020
Q2
$396K Sell
12,765
-2,699
-17% -$91.7K 0.04% 151
2020
Q1
$479K Sell
15,464
-527
-3% -$18K 0.05% 141
2019
Q4
$594K Sell
15,991
-211
-1% -$7.52K 0.03% 157
2019
Q3
$552K Sell
16,202
-961
-6% -$34.9K 0.02% 158
2019
Q2
$705K Sell
17,163
-369
-2% -$14.7K 0.03% 157
2019
Q1
$706K Buy
17,532
+817
+5% +$32.7K 0.03% 156
2018
Q4
$692K Sell
16,715
-369
-2% -$15.3K 0.03% 152
2018
Q3
$714K Sell
17,084
-422
-2% -$16.2K 0.02% 160
2018
Q2
$603K Sell
17,506
-316
-2% -$10.8K 0.02% 170
2018
Q1
$600K Sell
17,822
-896
-5% -$30.8K 0.02% 170
2017
Q4
$643K Hold
18,718
0.02% 167
2017
Q3
$634K Sell
18,718
-6,661
-26% -$214K 0.02% 168
2017
Q2
$809K Sell
25,379
-44,376
-64% -$1.4M 0.02% 161
2017
Q1
$2.26M Buy
69,755
+3,601
+5% +$114K 0.06% 134
2016
Q4
$2.04M Buy
66,154
+1,172
+2% +$35.8K 0.06% 133
2016
Q3
$2.09M Buy
64,982
+4,271
+7% +$143K 0.06% 137
2016
Q2
$2.03M Buy
60,711
+447
+0.7% +$14.3K 0.06% 139
2016
Q1
$1.7M Buy
60,264
+796
+1% +$22.7K 0.06% 137
2015
Q4
$1.82M Buy
59,468
+1,924
+3% +$60.5K 0.06% 137
2015
Q3
$1.72M Buy
57,544
+342
+0.6% +$11K 0.06% 142
2015
Q2
$1.82M Buy
57,202
+3,189
+6% +$104K 0.05% 149
2015
Q1
$1.78M Buy
54,013
+643
+1% +$20.4K 0.05% 145
2014
Q4
$1.58M Hold
53,370
0.04% 157
2014
Q3
$1.5M Sell
53,370
-1,208
-2% -$33.9K 0.04% 161
2014
Q2
$1.54M Sell
54,578
-1,366
-2% -$38.9K 0.04% 151
2014
Q1
$1.71M Sell
55,944
-108,172
-66% -$3.23M 0.05% 148
2013
Q4
$4.77M Sell
164,116
-4,841
-3% -$141K 0.15% 113
2013
Q3
$4.61M Sell
168,957
-2,550
-1% -$69.4K 0.16% 106
2013
Q2
$4.56M Buy
+171,507
New +$4.74M 0.17% 102

Other funds holding PFE

Eagle Global Advisors's PFE Position: Q2 2026 in Review

Eagle Global Advisors held its Pfizer (PFE) position steady in Q2 2026 at 13,800 shares worth $332K. The position accounts for 0.01% of the portfolio, ranked #232.

Eagle Global Advisors first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.33M in Q4 2021. 1,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Eagle Global Advisors held 13,800 shares of Pfizer worth $332K as of Q2 2026.
  • Eagle Global Advisors left its Pfizer share count unchanged in Q2 2026.
  • Pfizer made up 0.01% of Eagle Global Advisors's portfolio in Q2 2026, its #232 holding.
  • Eagle Global Advisors first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Eagle Global Advisors's Pfizer position peaked at $8.33M in Q4 2021.
  • 1,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Eagle Global Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.